Anti–tumor necrosis factor α therapy and the risk of lymphoma in rheumatoid arthritis: No clear answer
Open Access
- 3 June 2004
- journal article
- editorial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 50 (6) , 1703-1706
- https://doi.org/10.1002/art.20312
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Advances in targeted therapy: safety of biological agentsAnnals of the Rheumatic Diseases, 2003
- Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first‐degree relativesArthritis & Rheumatism, 2003
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- Tumor necrosis factor-α antagonists for the treatment of rheumatic diseasesCurrent Opinion in Rheumatology, 2002
- Anti-TNFα Therapy of Rheumatoid Arthritis: What Have We Learned?Annual Review of Immunology, 2001
- Lymphoma in Patients with Rheumatoid ArthritisDrug Safety, 1999
- Rheumatoid arthritis and cancer riskEuropean Journal Of Cancer, 1996
- Incidence of Cancer Among Patients With Rheumatoid ArthritisJNCI Journal of the National Cancer Institute, 1993
- The Pathophysiology of Tumor Necrosis FactorsAnnual Review of Immunology, 1992
- Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritisJournal of Chronic Diseases, 1978